Enable Accessibility Enable Accessibility

Press Releases and Position Statements

SEPTEMBER 7

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

SEPTEMBER 1

Joint Statement from Moderna and Takeda on the Investigation of Suspended Lots of Moderna’s COVID-19 Vaccine in Japan

AUGUST 28

Moderna and Takeda’s Response to the Incidents Announced by the Japanese Ministry of Health, Labour and Welfare (MHLW) associated with the Announced Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan

AUGUST 26

Notice of Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan (COVID-19 Vaccine Moderna Intramuscular Injection)

JUNE 20

Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government

MAY 21

Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan

MAY 10

Takeda Announces Positive Interim Safety and Immunogenicity Data from its Phase 1/2 Study of Moderna’s COVID-19 Vaccine Candidate (TAK-919) in Japan

APRIL 2

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

MARCH 15

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

MARCH 5

Takeda Submits New Drug Application to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan

FEBRUARY 24

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

JANUARY 21

Start of a Japanese Clinical Study of TAK-919, Moderna’s COVID-19 Vaccine Candidate

DECEMBER 2

COVID-19 and the Role of Diagnostic Testing for Asymptomatic and Pre-Symptomatic Individuals

DECEMBER 1

World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19

OCTOBER 29

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

OCTOBER 9

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

OCTOBER 1

19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium

AUGUST 7

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

AUGUST 3

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

MAY 26

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

MAY 7

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

APRIL 6

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

MARCH 25

Takeda Research & Development and COVID-19

MARCH 23

Coronavirus and Product Supply

MARCH 4

Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19